Impact of Prior Bisphosphonates Exposure on the Efficacy of Denosumab in Patients with Osteoporosis: A Prospective Cohort Study
Authors' conclusion
Compared with the BPs-then-DEN group, the DEN-only group demonstrated superior suppression of BTMs and greater improvement in THBMD, which may be partially attributable to the higher baseline BTMs in the DEN-only group.
Study context
- Population
- Postmenopausal women aged over 50 years with osteoporosis, with ≥ 12-month prior bisphosphonates (BPs) use or antiosteoporotic treatment-naïve
- Participants
- 132 women
- Exposure
- Denosumab (DEN)-only group vs BPs-then-DEN group
- DEN-onlyn = 91
- BPs-then-DENn = 41
- Outcome
- Suppression of BTMs
- Follow-up
- Months 12 and 24
Methodological detailspropensity score matching for sensitivity analyses
- Propensity score matching for sensitivity analyses
Main finding
As reported in the abstract
- DEN-only vs BPs-then-DEN: P < 0.05
- Adjusted for age at menopause, ALP, AST, UA, 25(OH)D, corrected calcium, and phosphorus
Observational data: associations, not effects.
Further findings
Median
| Outcome | BPs-then-DEN | DEN-only | P value |
|---|---|---|---|
| BMD increase in total hip (TH) · month 24Greater increase with DEN-only | 0.42% (IQR −1.18%–3.01%) | 2.43% (IQR −1.13%–6.06%) | P = 0.031 |
- Baseline bone turnover markers (BTMs) · higher in DEN-only
- P < 0.001
Baseline bone mineral density (BMD)
- No difference in baseline BMD between the two groups
Propensity score matching (PSM) sensitivity analysis
- PSM analysis further confirmed the results
Original publication
Impact of Prior Bisphosphonates Exposure on the Efficacy of Denosumab in Patients with Osteoporosis: A Prospective Cohort Study. Endocr Pract. Published 12 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →